公开(公告)号：US20240226243A9

公开(公告)日：2024-07-11

申请号：US18131560

申请日：2023-04-06

申请人： Applied Molecular Transport Inc.

发明人： Randall J. Mrsny ,  Tahir Mahmood

IPC分类号： A61K38/45 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K38/26 ,  A61K38/27 ,  A61K38/48 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/54 ,  C07K16/24

CPC分类号： A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90

摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

公开(公告)号：US20240131118A1

公开(公告)日：2024-04-25

申请号：US18131560

申请日：2023-04-05

申请人： Applied Molecular Transport Inc.

发明人： Randall J. Mrsny ,  Tahir Mahmood

IPC分类号： A61K38/45 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K38/26 ,  A61K38/27 ,  A61K38/48 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/54 ,  C07K16/24

CPC分类号： A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90

摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

公开(公告)号：US20230382971A1

公开(公告)日：2023-11-30

申请号：US18357979

申请日：2023-07-24

申请人： Emory University

发明人： Lily Yang ,  Erica Bozeman

IPC分类号： C07K14/705 ,  A61K47/69 ,  A61K47/62 ,  A61P35/02 ,  A61K49/00 ,  A61K49/18 ,  A61K51/08 ,  G01N33/574 ,  A61K31/4245 ,  A61K38/48 ,  A61K31/405 ,  A61K31/7088 ,  A61K45/06 ,  A61K38/17

CPC分类号： C07K14/70521 ,  B82Y5/00 ,  A61K47/62 ,  A61P35/02 ,  A61K49/0002 ,  A61K49/0093 ,  A61K49/1866 ,  A61K51/08 ,  C07K14/70596 ,  G01N33/574 ,  A61K47/6939 ,  A61K31/4245 ,  A61K38/4886 ,  C12Y304/21073 ,  A61K31/405 ,  A61K38/482 ,  A61K31/7088 ,  A61K45/06 ,  C12Y304/2408 ,  A61K38/177 ,  A61K47/6929

摘要： This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

公开(公告)号：US09867805B2

公开(公告)日：2018-01-16

申请号：US15139055

申请日：2016-04-26

申请人： University of Notre Dame du Lac

发明人： Mayland Chang ,  Shahriar Mobashery ,  Mijoon Lee

IPC分类号： A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  A61K31/38 ,  C07D331/02 ,  C07D409/12 ,  A61K38/48 ,  A61K38/49

CPC分类号： A61K31/38 ,  A61K38/482 ,  A61K38/4886 ,  A61K38/49 ,  C07D331/02 ,  C07D409/12 ,  C12Y304/21 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y304/24007 ,  C12Y304/24017 ,  C12Y304/24023 ,  C12Y304/24035

摘要： The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

公开(公告)号：US20170239335A1

公开(公告)日：2017-08-24

申请号：US15519435

申请日：2015-10-15

申请人： Piramal Enterprises Limited

发明人： Vandana SONAVARIA ,  Kamal Kumar UPADHYAY

IPC分类号： A61K38/49 ,  A61K47/10 ,  A61K31/675 ,  A61K47/26 ,  A61K9/08 ,  A61K9/00 ,  A61K38/12

CPC分类号： A61K38/49 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/522 ,  A61K31/65 ,  A61K31/675 ,  A61K31/69 ,  A61K38/09 ,  A61K38/12 ,  A61K38/166 ,  A61K38/22 ,  A61K38/2257 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  C12Y304/21073 ,  A61K2300/00

摘要： The present invention relates to a stable, non-aqueous and ready-to-use injectable composition of a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. The present invention also relates to a process for the preparation of the stable, non-aqueous and ready-to-use injectable composition of pharmaceutically active agent involving use of a non-solvent solvent system suitable for preparing a stabilized injectable composition comprising a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. It is not required to reconstitute the injectable composition of pharmaceutically active agent with water prior to administration, thereby rendering it an easy-to-use injectable composition.

公开(公告)号：US20170106059A1

公开(公告)日：2017-04-20

申请号：US15280673

申请日：2016-09-29

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA

发明人： Jaime F. Modiano ,  Daniel Vallera ,  Antonella Borgatti

IPC分类号： A61K38/48 ,  A61K38/18 ,  A61K38/16 ,  A61K9/00

CPC分类号： A61K38/482 ,  A61K9/0019 ,  A61K38/164 ,  A61K38/1808 ,  C12Y304/21073

摘要： In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging.

公开(公告)号：US20170044522A1

公开(公告)日：2017-02-16

申请号：US15337283

申请日：2016-10-28

申请人： BioAtla, LLC

发明人： Jay M. Short ,  Hwai Wen Chang ,  Gerhard Frey

IPC分类号： C12N15/10 ,  G01N33/68 ,  C12N9/68

CPC分类号： C12N15/102 ,  A61K38/00 ,  C07K7/06 ,  C07K14/3153 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57545 ,  C07K14/57563 ,  C12N9/16 ,  C12N9/50 ,  C12N9/6435 ,  C12N9/6459 ,  C12N9/6462 ,  C12N15/1058 ,  C12Y302/01035 ,  C12Y304/21007 ,  C12Y304/21069 ,  C12Y304/21073 ,  C12Y304/23015 ,  C12Y304/24029 ,  G01N33/54306 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/6854 ,  Y02A50/473

摘要： This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

摘要翻译： 本公开涉及从野生型正常生理条件下可逆地或不可逆地灭活的野生型蛋白质，特别是治疗性蛋白质产生条件活性生物蛋白质的方法。 例如，进化蛋白质在体温实际上是无活性的，但在较低温度下是活性的。

公开(公告)号：US09527878B2

公开(公告)日：2016-12-27

申请号：US14817690

申请日：2015-08-04

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  EASTERN MICHIGAN UNIVERSITY

发明人： Daniel A. Lawrence ,  Cory Emal ,  Jacqueline Cale ,  Enming Joe Su ,  Mark Warnock ,  Shih-Hon Li ,  Jeanne Ann Cupp

IPC分类号： C07H15/203 ,  A61K31/7034 ,  A61K38/17 ,  C07C69/94 ,  A61K31/235 ,  C07C271/22 ,  A61K31/27 ,  C07C311/29 ,  A61K31/18 ,  C07C235/68 ,  A61K31/166 ,  C07D213/82 ,  A61K31/444 ,  C07D295/192 ,  A61K31/495 ,  C07C311/49 ,  C07D295/26 ,  A61K31/50 ,  A61K31/5375 ,  C07C69/88 ,  C07C69/90 ,  C07C229/12 ,  C07C229/34 ,  C07C271/54 ,  C07H13/08 ,  A61K38/48 ,  C07D295/195

CPC分类号： C07H15/203 ,  A61K31/166 ,  A61K31/18 ,  A61K31/235 ,  A61K31/27 ,  A61K31/444 ,  A61K31/495 ,  A61K31/50 ,  A61K31/5375 ,  A61K31/7034 ,  A61K38/1741 ,  A61K38/482 ,  C07C69/88 ,  C07C69/90 ,  C07C69/94 ,  C07C229/12 ,  C07C229/34 ,  C07C235/68 ,  C07C271/22 ,  C07C271/54 ,  C07C311/29 ,  C07C311/49 ,  C07C2601/14 ,  C07D213/82 ,  C07D295/192 ,  C07D295/195 ,  C07D295/26 ,  C07H13/08 ,  C12Y304/21073

摘要： The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

公开(公告)号：US20160199259A1

公开(公告)日：2016-07-14

申请号：US15080210

申请日：2016-03-24

申请人： BNCP CORPORATION

发明人： Gi-Bum OH

IPC分类号： A61J1/20 ,  A61J1/14 ,  A61K31/397 ,  A61K31/407 ,  A61K31/513 ,  A61K9/00 ,  A61K31/341 ,  A61K38/48 ,  A61K31/5365 ,  A61K31/546 ,  A61K31/43 ,  A61J1/10 ,  A61K31/426

CPC分类号： A61J1/10 ,  A61J1/1462 ,  A61J1/201 ,  A61J1/2051 ,  A61J1/2065 ,  A61J1/2089 ,  A61K9/0019 ,  A61K31/341 ,  A61K31/397 ,  A61K31/407 ,  A61K31/426 ,  A61K31/43 ,  A61K31/513 ,  A61K31/5365 ,  A61K31/546 ,  A61K38/482 ,  C12Y304/21073

摘要： The present invention relates to unitary bottle for injection, more particularly, to a unitary medicine bottle having an integral structure where a medicine container is easily connected with a plastic container including a solution at a completely sterilized state so that powdered, freeze-dried or liquid medicine is mixed with the solution with one touch for a short time. The unitary medicine bottle for injection according to the present invention comprises: a plastic container equipped with a coupling member connected with a medicine container at one end and a releasing member for releasing a liquid medicine to be at the other end; a protection cap integrally formed with the coupling member to accept the medicine container; and a flue needle which moves forward in a direction of the medicine container and perforates a stopper of the medicine container and is inserted in the coupling member connecting the plastic container with the medicine container.

摘要翻译： 本发明涉及一体式注射用瓶，更具体地说，涉及具有一体结构的单一药瓶，其中药容器容易地与包含完全灭菌状态的溶液的塑料容器连接，使得粉末状，冷冻干燥或液体 药物与溶液混合在一起很短时间。 根据本发明的单一注射用药瓶包括：塑料容器，其具有连接部件，其一端与药物容器连接;释放部件，用于释放另一端的药液; 与所述联接构件一体地形成以接受所述药剂容器的保护帽; 以及烟道针，其沿药物容器的方向向前移动并穿过药剂容器的止动件，并且插入到将塑料容器与药剂容器连接的联接构件中。

公开(公告)号：US20160144001A1

公开(公告)日：2016-05-26

申请号：US14949266

申请日：2015-11-23

申请人： Northwestern University

发明人： Douglas E. Vaughan ,  Mesut Eren ,  Aaron T. Place ,  Toshio Miyata

IPC分类号： A61K38/48 ,  G01N33/74 ,  A61K31/341

CPC分类号： A61K38/482 ,  A61K31/341 ,  A61K31/381 ,  A61K31/495 ,  A61K38/49 ,  A61K45/06 ,  C07K14/50 ,  C12Y304/21068 ,  C12Y304/21073 ,  G01N2333/50 ,  G01N2800/52 ,  A61K2300/00

摘要： The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA.

摘要翻译： 本发明提供用于治疗特征在于成纤维细胞生长因子23（FGF23）升高的病症的组合物，系统和方法，组合物包含：i）导致尿激酶纤溶酶原激活物（uPA）和/或组织的表达增加的试剂 纤溶酶原激活剂（tPA），ii）纯化的uPA和/或纯化的tPA。